Answer

Caution is required. Iron supplements can significantly reduce the efficacy of certain antiretrovirals (ARVs), specifically integrase inhibitors, by interfering with drug absorption.

Evidence Assessment

Quality Score: 40 (Tier C - Limited Evidence) The assessment is based on curated pharmacological interaction databases (DDInter 2.0) rather than a series of randomized controlled trials. While the biochemical mechanism of chelation is well-understood, specific clinical trial data on the magnitude of the interaction across all ARV classes is limited.

Clinical Evidence

The primary concern with combining iron and antiretrovirals is the formation of insoluble complexes (chelation). Polyvalent cations, including ferric ($\text{Fe}^{3+}$) and ferrous ($\text{Fe}^{2+}$) iron, can bind to the drug molecules in the gastrointestinal tract, preventing the medication from being absorbed into the bloodstream.

This interaction is particularly critical for the following medications: * Integrase Strand Transfer Inhibitors (INSTIs): Specifically Dolutegravir and Bictegravir. These drugs have a high affinity for metal cations. When iron is present in the gut simultaneously, it binds to the drug, leading to decreased plasma concentrations of the antiretroviral, which may result in suboptimal viral suppression and the potential development of drug-resistant HIV strains [DDInter 2.0].

Practical Guidance

If iron supplementation is clinically necessary while taking an integrase inhibitor, timing is the primary method of management: * Timing: To avoid the interaction, iron should be administered at least 2 hours before or 6 hours after the dose of the antiretroviral. * Forms: This interaction occurs regardless of whether the iron is in the form of ferrous sulfate, gluconate, or fumarate. * Population: This is a critical consideration for patients with HIV who also suffer from iron-deficiency anemia, a common comorbidity.

Safety & Interactions

Verdict: Caution / Avoid simultaneous administration.

• Contraindication: Do not take iron supplements at the same time as Dolutegravir or Bictegravir.
• Drug Class & Mechanism: Integrase Inhibitors. The mechanism is chelation, where the metal ion (Iron) binds to the drug molecule, creating a complex that cannot be absorbed by the intestinal mucosa.
• Clinical Management:
  1. Stagger dosing (Iron $\rightarrow$ 2-6 hour gap $\rightarrow$ ARV).
  2. Monitor viral load closely if iron supplementation is initiated to ensure the ARV remains effective.
  3. Consult a healthcare provider to determine if an alternative ARV regimen (one with fewer cation interactions) is appropriate.
• High-Risk Populations: Patients with severe anemia requiring high-dose intravenous iron may avoid this specific GI interaction, but oral supplementation remains high-risk. Always coordinate with an infectious disease specialist.